Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

Abstract Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refractory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2009, Vol.15 (1), p.109-117
Main Authors: Devetten, Marcel P, Hari, Parameswaran N, Carreras, Jeanette, Logan, Brent R, van Besien, Koen, Bredeson, Christopher N, Freytes, César O, Gale, Robert Peter, Gibson, John, Giralt, Sergio A, Goldstein, Steven C, Gupta, Vikas, Marks, David I, Maziarz, Richard T, Vose, Julie M, Lazarus, Hillard M, Anderlini, Paolo
Format: Article
Language:English
Subjects:
Allogeneic transplantation
Graft vs Host Disease
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cell Transplantation - statistics & numerical data
Hodgkin Disease - complications
Hodgkin Disease - mortality
Hodgkin Disease - therapy
Hodgkin lymphoma
Humans
Recurrence
Retrospective Studies
Risk Factors
Salvage Therapy - methods
Survival Analysis
Tissue Donors
Transplantation Conditioning - methods
Transplantation Conditioning - statistics & numerical data
Transplantation, Homologous
Unrelated
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Myeloablative allogeneic hematopoietic cell transplantation (HCT) may cure patients with relapsed or refractory Hodgkin lymphoma (HL), but is associated with a high treatment-related mortality (TRM). Reduced-intensity and nonmyeloablative (RIC/NST) conditioning regimens aim to lower TRM. We analyzed the outcomes of 143 patients undergoing unrelated donor RIC/NST HCT for relapsed and refractory HL between 1999 and 2004 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Patients were heavily pretreated, including autologous HCT in 89%. With a median follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% (95% confidence interval [CI] 10%-21%) and 33% (95% CI 25%-41%), respectively. The probabilities of progression free survival (PFS) and overall survival (OS) were 30% and 56% at 1 year and 20% and 37% at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS)
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2008.11.011